Premium
Thyroid eye disease: Redefining its management—A review
Author(s) -
Jain Amy P.,
JaruAmpornpan Pimkwan,
Douglas Raymond S.
Publication year - 2021
Publication title -
clinical and experimental ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.3
H-Index - 74
eISSN - 1442-9071
pISSN - 1442-6404
DOI - 10.1111/ceo.13899
Subject(s) - medicine , diplopia , disease , disease management , intervention (counseling) , eye disease , quality of life (healthcare) , intensive care medicine , thyroid , thyroid disease , optometry , surgery , pathology , nursing , parkinson's disease
Thyroid eye disease (TED) is a debilitating, vision threatening disease that dramatically alters patients' quality of life. Until recently, the management of TED is a long arduous course with supportive therapy, followed by an extensive surgical treatment plan to reverse the disease endpoints. Teprotumumab offers an early, safe therapeutic intervention to help reverse disease end points such as diplopia and proptosis and improve quality of life.